💼 Business 6h ago · Ekta Bagri

Does Cobenfy Have the Potential to Become a Top Drug for BMY?

Quartz (QZ)
Global business news for the new economy
View Channel →
Source ↗ 👁 0 💬 0
BMY's Cobenfy gains traction with $155M in 2025 sales, outpacing peers and showing strong uptake as Bristol Myers eyes new indications and growth.

Comments (0)

Sign in to join the discussion

More Like This

Bessent, Powell warned bank CEOs about Anthropic model risks, sources say
All News · 4h ago
China March PPI returns to growth for first time since 2022, CPI misses forecasts
All News · 4h ago
Japan rules out major domestic risks from private credit for now
All News · 4h ago
China sees first producer inflation in over three years
All News · 4h ago
Form 13D/A Riley Exploration Permian For: 9 April
All News · 4h ago
Form 144 METHANEX CORP For: 9 April
All News · 4h ago